GlaxoSmithKline Pharmaceuticals500660Quarterly results
Board approves Q2 results, new Ethics & Compliance Head and Walker Chandiok as statutory auditors
Board meeting on 3rd November 2026: Mr. Sandeep Seth appointed Head - Ethics & Compliance with effect from that day.
By ScoutQuest · · 3 min read
| Line item | Latest | Year ago | YoY | Prev qtr | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 118357 | 97994 | +20.8% | 93844 | +26.1% |
| Total income | 125635 | 101351 | +24% | 98220 | +27.9% |
| Profit before tax | 45934 | 35400 | +29.8% | 32245 | +42.5% |
| Profit after tax | 33588 | 25749 | +30.4% | 23718 | +41.6% |
| Total comprehensive income | 33588 | 25749 | +30.4% | 23718 | +41.6% |
| Basic EPS | 19.83 | 15.20 | +30.5% | 14.00 | +41.6% |
- Total income
- Latest 125635; Year ago 101351 (+24%); Prev qtr 98220 (+27.9%)
- Profit after tax
- Latest 33588; Year ago 25749 (+30.4%); Prev qtr 23718 (+41.6%)
- Period
- 3 months ended 30.09.2026
Also decided at the meeting
- Mr. Sandeep Seth appointed as Head - Ethics & Compliance effective 3rd November 2026.
- Approved appointment of M/s Walker Chandiok & Co LLP as Statutory Auditors for a first term of five years from FY 2027-28 till the 107th AGM (FY 2031-32), subject to Members' approval.
Notes to the results
- Other Income for the quarter and six months ended 30th September 2026 includes interest on Income Tax refund of Rs. 4209 lakhs (standalone note).
- Standalone other income for six months includes Rs. 1800 lakhs dividend from wholly owned subsidiary Biddle Sawyer Limited.
- Standalone exceptional items credit for year ended 31st March 2026 of Rs. 264 lakhs is on account of profit on sale of surplus residential properties.
What the board decided
Three items came up at the meeting held on 3rd November 2026, which ran from 3.45 p.m. to 6.00 p.m.: the quarterly results, a senior management appointment, and a change of statutory auditors.
Senior management change
- Mr. Sandeep Seth has been appointed Head - Ethics & Compliance, effective 3rd November 2026.
- The update records no relationship with any director.
- His profile states more than 20 years of experience in ethics, compliance and governance across pharmaceuticals, consumer healthcare and health insurance, with earlier roles at Opella, Pfizer, MSD Pharma and Max Bupa Health. In the new role he will be part of the APAC Compliance leadership team and the India Leadership Team.
Change in statutory auditors
- The board, on the Audit Committee's recommendation, approved the appointment of M/s Walker Chandiok & Co LLP, Chartered Accountants, as statutory auditors for a first term of five consecutive years.
- The term runs from financial year 2027-28 until the conclusion of the 107th Annual General Meeting, in respect of financial year 2031-32.
- The appointment is subject to the approval of members at the ensuing Annual General Meeting.
- The firm's profile states it was established in 1935, has nineteen other offices in India and ninety-nine partners.
Second quarter, standalone (unaudited)
- Revenue from operations: 117991 (Rs. in lakhs)
- Total income: 125268 (Rs. in lakhs)
- Profit before exceptional items and tax: 45758 (Rs. in lakhs)
- Profit for the period: 33462 (Rs. in lakhs)
- Basic and diluted EPS before Exceptional Items: 19.76 (Rs.)
Second quarter, consolidated (unaudited)
- Revenue from operations: 118357 (Rs. in lakhs)
- Total income: 125635 (Rs. in lakhs)
- Profit before exceptional items and tax: 45934 (Rs. in lakhs)
- Profit for the period: 33588 (Rs. in lakhs)
- Basic and diluted EPS before Exceptional Items: 19.83 (Rs.)
Half year and full year comparison
- Standalone Profit for the period for the six months ended 30th September 2026 was 58795 (Rs. in lakhs), against 45970 (Rs. in lakhs) for the six months ended 30th September 2025.
- Standalone Profit for the year ended 31st March 2026 (audited) was 101182 (Rs. in lakhs).
- Consolidated Profit for the period for the six months ended 30th September 2026 was 57306 (Rs. in lakhs), against 46250 (Rs. in lakhs) a year earlier.
Items inside other income
- Other income for the quarter and six months ended 30th September 2026 includes interest on Income Tax refund of Rs. 4209 lakhs.
- Other income for the six months ended 30th September 2026 also includes Rs. 1800 lakhs of dividend from the wholly owned subsidiary, Biddle Sawyer Limited.
These two items sit within other income rather than revenue from operations, which readers may want to keep in mind when comparing quarters.
Other points from the notes
- The results were reviewed by the Audit Committee and approved by the Board at their respective meetings held on 03rd November 2026, and the statutory auditors carried out a limited review of the standalone financial results.
- The company has only one reportable segment, Pharmaceuticals, so no separate segment disclosures have been made.
- The exceptional item credit of Rs. 264 lakhs for the year ended 31st March 2026 relates to profit on sale of surplus residential properties.
₹118357 lakhConsolidated Revenue from operations, (Rs. in lakhs
Profit before tax, year-ago quarter35400 (Rs. in Lakhs)
Standalone Profit for the period, (Rs. in lakhs₹33462 lakh
Profit after tax, year-ago quarter25749 (Rs. in Lakhs)
Profit after tax, quarter23718 (Rs. in Lakhs)
Also from GlaxoSmithKline Pharmaceuticals
GSK India to foray into haemato-oncology with BLENREP launch; adds Calpol 500 and Eltroxin line extensions in Q2 FY2027
3 Nov 2026
Q2 results, new Ethics & Compliance Head and new Statutory Auditors approved by board
3 Nov 2026
GSK Pharmaceuticals schedules digital group investors/analysts meet on 4 November 2026
28 Oct 2026
More numbers
- Standalone Revenue from operations, Q2 FY27 (Rs. in lakhs)117991
- Standalone Profit for the period, Q2 FY27 (Rs. in lakhs)33462
- Standalone Profit for the period, six months (Rs. in lakhs)58795
- Standalone Basic and diluted EPS before Exceptional Items, Q2 (Rs.)19.76
- Interest on Income Tax refund in other income, Q2/H1 (Rs. in lakhs)4209
- Total income, latest quarter125635 (Rs. in Lakhs)
- Total income, year-ago quarter101351 (Rs. in Lakhs)
- Total income, previous quarter98220 (Rs. in Lakhs)
- Total comprehensive income, latest quarter33588 (Rs. in Lakhs)
- Total comprehensive income, year-ago quarter25749 (Rs. in Lakhs)
- Total comprehensive income, previous quarter23718 (Rs. in Lakhs)
- Profit after tax, latest quarter33588 (Rs. in Lakhs)
- Profit after tax, year-ago quarter25749 (Rs. in Lakhs)
- Profit after tax, previous quarter23718 (Rs. in Lakhs)
- Revenue from operations, latest quarter118357 (Rs. in Lakhs)
- Revenue from operations, year-ago quarter97994 (Rs. in Lakhs)
- Revenue from operations, previous quarter93844 (Rs. in Lakhs)
- Profit before tax, latest quarter45934 (Rs. in Lakhs)
- Profit before tax, year-ago quarter35400 (Rs. in Lakhs)
- Profit before tax, previous quarter32245 (Rs. in Lakhs)
Source: BSE · 3 Nov 2026
Nothing here is a view, opinion or recommendation of ScoutQuest, its parent, directors or employees. ScoutQuest is a technology company: this page was assembled automatically from public sources using artificial intelligence, and may contain errors or omissions. Confirm everything against the original source before you act on it. Any use of this page is at your own risk, and neither ScoutQuest nor its parent, directors or employees accepts liability for it.